Buy AbbVie on the Dip: Pipeline Momentum and Yield Make This a Tactical Buy
AbbVie pulled back recently, leaving the stock around $208 with a 3.2% yield and strong free cash flow. Fundamentals - namely Skyrizi and Rinvoq growth, a $17.8B FCF run-rate, and an enterprise value of $428B - argue this is a tactical buying opportunity. We reiterate Buy with a clear entry at $205.00, stop at $195.00 and target $235.00 over a 180 …